AstraZeneca lung cancer drug receives FDA approval

The US Food and Drug Administration (FDA) has granted full approval for AstraZeneca’s Tagrisso (osimertinib) tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR).

Spotlight

Spotlight

Related News